PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

First-in-human clinical trial confirms HIV vaccine approach by IAVI and Scripps Research

The experimental vaccine primed the immune system as the first stage in the production of broadly neutralizing antibodies

2021-02-03
(Press-News.org) NEW YORK and LA JOLLA, CA--A phase 1 clinical trial testing a novel vaccine approach to prevent HIV has produced promising results, IAVI and Scripps Research announced today. The vaccine showed success in stimulating production of rare immune cells needed to start the process of generating antibodies against the fast-mutating virus; the targeted response was detected in 97 percent of participants who received the vaccine.

"This study demonstrates proof of principle for a new vaccine concept for HIV, a concept that could be applied to other pathogens, as well," says William Schief, Ph.D., a professor and immunologist at Scripps Research and executive director of vaccine design at IAVI's Neutralizing Antibody Center, whose laboratory developed the vaccine. "With our many collaborators on the study team, we showed that vaccines can be designed to stimulate rare immune cells with specific properties, and this targeted stimulation can be very efficient in humans. We believe this approach will be key to making an HIV vaccine and possibly important for making vaccines against other pathogens."

Schief presented the results on behalf of the study team at the International AIDS Society HIV Research for Prevention (HIVR4P) virtual conference today.

The study sets the stage for additional clinical trials that will seek to refine and extend the approach--with the long-term goal of creating a safe and effective HIV vaccine. As a next step, IAVI and Scripps Research are partnering with the biotechnology company Moderna to develop and test an mRNA-based vaccine that harnesses the approach to produce the same beneficial immune cells. Using mRNA technology could significantly accelerate the pace of HIV vaccine development.

HIV, which affects more than 38 million people globally, is known to be among the most difficult viruses to target with a vaccine, in large part because it constantly evolves into different strains to evade the immune system.

"These exciting findings emerge from remarkably creative, innovative science and are a testament to the research team's talent, dedication and collaborative spirit, and to the generosity of the trial participants," says Mark Feinberg, M.D., Ph.D., president and CEO of IAVI. "Given the urgent need for an HIV vaccine to rein in the global epidemic, we think these results will have broad implications for HIV vaccine researchers as they decide which scientific directions to pursue. The collaboration among individuals and institutions that made this important and exceptionally complex clinical trial so successful will be tremendously enabling to accelerate future HIV vaccine research."

One in a million

For decades now, HIV researchers have pursued the holy grail of stimulating the immune system to create rare but powerful antibodies that can neutralize diverse strains of HIV. Known as "broadly neutralizing antibodies," or bnAbs, these specialized blood proteins could attach to HIV spikes, proteins on the virion surface that allow the virus to enter human cells, and disable them via important yet difficult-to-access regions that don't vary much from strain to strain.

"We and others postulated many years ago that in order to induce bnAbs, you must start the process by triggering the right B cells--cells that have special properties giving them potential to develop into bnAb-secreting cells," Schief says. "In this trial, the targeted cells were only about one in a million of all naïve B cells. To get the right antibody response, we first need to prime the right B cells. The data from this trial affirms the ability of the vaccine immunogen to do this."

The priming step would be the first stage of a multi-step vaccine regimen aimed at eliciting many different types of bnAbs, he says.

Promise beyond HIV

The strategy of targeting naïve B cells with specific properties is called "germline-targeting," as these young B cells display antibodies encoded by unmutated, or "germline" genes. Researchers believe the approach could also be applied to vaccines for other challenging pathogens such as influenza, dengue, Zika, hepatitis C viruses and malaria.

"This is a tremendous achievement for vaccine science as a whole," says Dennis Burton, Ph.D., professor and chair of the Department of Immunology and Microbiology at Scripps Research, scientific director of the IAVI Neutralizing Antibody Center and director of the NIH Consortium for HIV/AIDS Vaccine Development. "This clinical trial has shown that we can drive immune responses in predictable ways to make new and better vaccines, and not just for HIV. We believe this type of vaccine engineering can be applied more broadly, bringing about a new day in vaccinology."

The clinical trial, IAVI G001, was sponsored by IAVI and took place at two sites: George Washington University (GWU) in Washington, D.C., and the Fred Hutchinson Cancer Research Center (Fred Hutch) in Seattle, enrolling 48 healthy adult volunteers. Participants received either a placebo or two doses of the vaccine compound, eOD-GT8 60mer, along with an adjuvant developed by the pharmaceutical company GSK. Julie McElrath, M.D., Ph.D., senior vice president and director of Fred Hutch's Vaccine and Infectious Disease Division, and David Diemert, M.D., professor of medicine at GWU School of Medicine and Health Sciences, were lead investigators at the trial sites.

"This is a landmark study in the HIV vaccine field, demonstrating success in the first step of a pathway to induce broad neutralizing antibodies against HIV-1," McElrath says. "The novel design of the immunogen, the clinical trial and the molecular B cell analyses provide a roadmap to accelerate further progress toward an HIV vaccine."

Wide network of collaborators

Funding from the Bill & Melinda Gates Foundation, through the Collaboration for AIDS Vaccine Discovery, supported a wide network of partners conducting complex analyses.

The critical assay used to judge the vaccine candidate, epitope-specific single B cell sorting and B cell receptor (BCR) sequencing, was developed and carried out by teams at the NIH Vaccine Research Center, led by Adrian McDermott, Ph.D. (chief of the Vaccine Immunology Program), Richard Koup, M.D. (deputy director and chief of the Immunology Laboratory and Immunology Section), and research scientist David Leggat, Ph.D.; and at Fred Hutch, led by McElrath and senior staff scientist Kristen Cohen, Ph.D. Study design and data analysis were led by staff scientists Allan deCamp, Ph.D., Greg Finak, Ph.D., and Jimmy Fulp at the Vaccine Immunology Statistical Center at Fred Hutch, with assistance from the Schief lab.

INFORMATION:

IAVI and Scripps Research developed the vaccine candidate with funding from the Bill & Melinda Gates Foundation, an HIV Vaccine Research and Development grant (P01 AI094419, titled "Optimizing HIV immunogen-BCR interactions for vaccine development") from the National Institute of Allergy and Infectious Diseases (NIAID), the Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery (CHAVI-ID) at the NIAID and Scripps Research, and the Scripps Consortium for HIV/AIDS Vaccine Development (CHAVD). Other collaborating organizations include Duke Human Vaccine Institute, Karolinska Institutet and La Jolla Institute.

Research at the IAVI Neutralizing Antibody Center that contributed to the development of the vaccine candidate, eOD-GT8 60mer, was also made possible by the government of the Netherlands through the Minister of Foreign Trade & Development Cooperation and through the generous support of the American people through the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) through the United States Agency for International Development (USAID). The contents are the responsibility of IAVI and Scripps Research and do not necessarily reflect the views of USAID or the United States government.

About IAVI IAVI is a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges including HIV and tuberculosis. Its mission is to translate scientific discoveries into affordable, globally accessible public health solutions. Read more at iavi.org.

About Scripps Research Scripps Research is a private, nonprofit biomedical institute ranked the most influential in the world for its impact on innovation. With campuses in La Jolla, California, and Jupiter, Florida, we are advancing human health through profound discoveries that can be translated into solutions for pressing medical concerns around the globe. Our drug discovery and development division, Calibr, works hand-in-hand with scientists across disciplines to bring new medicines to patients as quickly and efficiently as possible, while teams at Scripps Research Translational Institute harness genomics, digital medicine and cutting-edge informatics to understand individual health and render more effective healthcare. Scripps Research also trains the next generation of leading scientists at our Skaggs Graduate School, consistently named among the top 10 U.S. programs for chemistry and biological sciences. Learn more at http://www.scripps.edu.



ELSE PRESS RELEASES FROM THIS DATE:

Research indicates gender disparity in academic achievement and leadership positions

Research indicates gender disparity in academic achievement and leadership positions
2021-02-03
CHARLOTTE, N.C. - Feb. 3, 2021 - New research on gender inequality indicates that fewer leadership prospects in the workplace apply even to women who show the most promise early on in their academic careers. Jill Yavorsky, an assistant professor of sociology at UNC Charlotte, co-led the study, "The Under-Utilization of Women's Talent: Academic Achievement and Future Leadership Positions," with Yue Qian, an assistant professor of sociology at the University of British Columbia. In their paper, published in a leading social science journal, Social Forces, the social scientists discovered that men supervise more individuals ...

Study examines role of biomarkers to evaluate kidney injury in cancer patients

2021-02-03
ROCHESTER, Minn. -- A study by Mayo Clinic researchers published in Kidney International Reports finds that immune checkpoint inhibitors, may have negative consequences in some patients, including acute kidney inflammation, known as interstitial nephritis. Immune checkpoint inhibitors are used to treat cancer by stimulating the immune system to attack cancerous cells. "Immune checkpoint inhibitors have improved the prognosis for patients with a wide range of malignancies including melanoma, non-small cell lung cancer and renal cancer," says Sandra Herrmann, M.D., ...

Feed Fido fresh human-grade dog food to scoop less poop

2021-02-03
URBANA, Ill. - For decades, kibble has been our go-to diet for dogs. But the dog food marketplace has exploded in recent years, with grain-free, fresh, and now human-grade offerings crowding the shelves. All commercial dog foods must meet standards for complete and balanced nutrition, so how do consumers know what to choose? A new University of Illinois comparison study shows diets made with human-grade ingredients are not only highly palatable, they're extremely digestible. And that means less poop to scoop. Up to 66% less. "Based on past research we've conducted I'm not surprised with the results when feeding human-grade compared to an extruded dry diet," says Kelly Swanson, the Kraft Heinz Company Endowed Professor in Human Nutrition in the ...

MSK scientists learn how genes and environment conspire in pancreatic cancer development

2021-02-03
Like weeds sprouting from cracks in the pavement, cancer often forms in sites of tissue damage. That damage could be an infection, a physical wound, or some type of inflammation. Common examples include stomach cancer caused by H. pylori infection, Barrett's esophagus caused by acid reflux, and even smoking-induced lung cancer. Exactly how tissue damage colludes with genetic changes to promote cancer isn't fully understood. Most of what scientists know about cancer concerns advanced stages of the disease. That's especially true for cancers such as pancreatic cancer that are usually diagnosed very late. Researchers ...

Spanish scientists identify a mechanism through which dendritic cells improve their antiviral and immunotherapy strategies

Spanish scientists identify a mechanism through which dendritic cells improve their antiviral and immunotherapy strategies
2021-02-03
Researchers at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) led by Professor Francisco Sánchez-Madrid have found that dendritic cells, which initiate specific immune responses, can reprogram their genes to improve their immune response. The results of the study, funded by Fundación 'la Caixa' and published today in Science Advances, could have important applications in the development of new vaccination and immunotherapy strategies. Dendritic cells are professional antigen-presenting cells that initiate adaptive or specific immune responses. As described by the research team, "dendritic cells capture possible pathogenic agents in different tissues and entry sites, process their components, and transport them to lymph nodes. Here, they ...

Eavesdropping marmosets understood other monkeys' conversations - and they judged

2021-02-03
Captive marmosets that listened in on recorded vocal interactions between other monkeys appeared to understand what they overheard - and formed judgements about one of the interlocutors as a result, according to behavioral analyses and thermal measurements that corresponded with the marmosets' emotional states. The findings suggest that the eavesdropping monkeys perceived these vocalizations as "conversations" rather than isolated elements and indicate that, on the whole, they prefer to interact with cooperative rather than noncooperative individuals. However, the researchers observed notable differences in how male or female and breeder or helper animals (those without their own offspring) reacted after eavesdropping. While behavioral ...

Smartwatch sensors enable remote monitoring & treatment guidance for Parkinson's patients

Smartwatch sensors enable remote monitoring & treatment guidance for Parkinsons patients
2021-02-03
Scientists have developed a monitoring system based on commercial smartwatches that can detect movement issues and tremors in patients with Parkinson's disease. The system was tested in a study involving 343 patients - including 225 who the researchers followed for 6 months. The system gave evaluations that matched a clinician's estimates in 94% of the subjects. The findings suggest the platform could allow clinicians to remotely monitor the progression of a patient's condition and adjust medication plans accordingly to improve outcomes. Parkinson's disease is marked by a breakdown in voluntary movement ...

Impact of spokesperson identity on sharing of public health messages

2021-02-03
Participants in an international survey study reported greater willingness to reshare a call for social distancing if the message was endorsed by well-known immunology expert Anthony Fauci, rather than a government spokesperson or celebrity. Ahmad Abu-Akel of the University of Lausanne, Switzerland, and colleagues Andreas Spitz and Robert West of the École Polytechnique Fédérale de Lausanne, report these findings in the open-access journal PLOS ONE on February 3. Previous research has extensively explored how to maximize the effectiveness of public health messages by altering their style and content. However, relatively few studies have examined the impact of spokesperson identity on the effectiveness of health messages, especially during crises like the ongoing COVID-19 ...

Forming sound memories: Autism gene plays key aspect in birdsong

Forming sound memories: Autism gene plays key aspect in birdsong
2021-02-03
DALLAS - Feb. 3, 2021 - Inactivating a gene in young songbirds that's closely linked with autism spectrum disorder (ASD) prevents the birds from forming memories necessary to accurately reproduce their fathers' songs, a new study led by UT Southwestern shows. The findings, published online today in Science Advances, may help explain the deficits in speech and language that often accompany ASD and could eventually lead to new treatments specifically targeting this aspect of the disorder. Study leader Todd Roberts, Ph.D., associate professor of neuroscience and a member of the Peter O'Donnell Jr. Brain Institute at UT Southwestern, explains that the vocalizations that comprise a central part of human communication are relatively unique among ...

Scientists propose new way to detect emotions using wireless signals

2021-02-03
A novel artificial intelligence (AI) approach based on wireless signals could help to reveal our inner emotions, according to new research from Queen Mary University of London. The study, published in the journal PLOS ONE, demonstrates the use of radio waves to measure heartrate and breathing signals and predict how someone is feeling even in the absence of any other visual cues, such as facial expressions. Participants were initially asked to watch a video selected by researchers for its ability to evoke one of four basic emotion types; anger, sadness, joy and pleasure. ...

LAST 30 PRESS RELEASES:

Are lifetimes of big appliances really shrinking?

Pink skies

Monkeys are world’s best yodellers - new research

Key differences between visual- and memory-led Alzheimer’s discovered

% weight loss targets in obesity management – is this the wrong objective?

An app can change how you see yourself at work

NYC speed cameras take six months to change driver behavior, effects vary by neighborhood, new study reveals

New research shows that propaganda is on the rise in China

Even the richest Americans face shorter lifespans than their European counterparts, study finds

Novel genes linked to rare childhood diarrhea

New computer model reveals how Bronze Age Scandinavians could have crossed the sea

Novel point-of-care technology delivers accurate HIV results in minutes

Researchers reveal key brain differences to explain why Ritalin helps improve focus in some more than others

Study finds nearly five-fold increase in hospitalizations for common cause of stroke

Study reveals how alcohol abuse damages cognition

Medicinal cannabis is linked to long-term benefits in health-related quality of life

Microplastics detected in cat placentas and fetuses during early pregnancy

Ancient amphibians as big as alligators died in mass mortality event in Triassic Wyoming

Scientists uncover the first clear evidence of air sacs in the fossilized bones of alvarezsaurian dinosaurs: the "hollow bones" which help modern day birds to fly

Alcohol makes male flies sexy

TB patients globally often incur "catastrophic costs" of up to $11,329 USD, despite many countries offering free treatment, with predominant drivers of cost being hospitalization and loss of income

Study links teen girls’ screen time to sleep disruptions and depression

Scientists unveil starfish-inspired wearable tech for heart monitoring

Footprints reveal prehistoric Scottish lagoons were stomping grounds for giant Jurassic dinosaurs

AI effectively predicts dementia risk in American Indian/Alaska Native elders

First guideline on newborn screening for cystic fibrosis calls for changes in practice to improve outcomes

Existing international law can help secure peace and security in outer space, study shows

Pinning down the process of West Nile virus transmission

UTA-backed research tackles health challenges across ages

In pancreatic cancer, a race against time

[Press-News.org] First-in-human clinical trial confirms HIV vaccine approach by IAVI and Scripps Research
The experimental vaccine primed the immune system as the first stage in the production of broadly neutralizing antibodies